Tamer Behman, MD
Internal Medicine · Carteret, NJNPI 1730257619
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $102,700 of the $103,276 with a category attached, or 99.4%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 99.9% of it on its own, with 3 other manufacturers making up the rest. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $2197.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$103K
- Dexcom, Inc.$72
- Bristol Myers Squibb$17
- Biogen$11
What the payments were for
- Consulting fees$102,70099%
- Food & beverage$1010%
- Education$4750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $103,175 |
| Dexcom, Inc. | 4 | $72 |
| Bristol Myers Squibb | 1 | $17 |
| Biogen | 1 | $11 |
How this compares
$103,276 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,682 |
| Metoprolol Succinate | 46 | $605 |
| Fluticasone Propionate | 26 | $415 |
| Pantoprazole Sodium | 41 | $313 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $274 |
| Rosuvastatin Calcium | 15 | $269 |
| Ibuprofen | 18 | $260 |
| Atorvastatin Calcium | 26 | $245 |
| Naproxen | 19 | $230 |
| Methocarbamol | 13 | $220 |
| Quetiapine Fumarate | 18 | $215 |
| Gabapentin | 18 | $193 |
| Omeprazole | 13 | $154 |
| Simvastatin | 34 | $149 |
| Losartan Potassium | 42 | $144 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Carteret
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.